Table 1.

Schematic representation of molecular structure, ionicity, and biodistribution of GBCAs, as well as approval according to European Medicines Agency (EMA) and Food and Drug Administration (FDA).

Active Principle	Commercial	Manufacturer	Structure	Charge	Distribution	EMA	FDA
Gadoterate meglumine	Dotarem® Clariscan®	Guerbet, Aulnay-sous-Bois, France	Cyclic	Ionic	ECSA	Approved	Approved
Gadobutrol	Gadavist® Gadovist®	Bayer, Milano, Italy	Cyclic	Non-Ionic	ECSA	Approved	Approved
Gadopentetate dimeglumine	Magnevist®	Bayer Pharma, Leverkusen, Germany	Linear	Ionic	ECSA	Suspended	Approved
Gadodiamide	Omniscan®	GE Healthcare, Milano, Italy	Linear	Non-Ionic	ECSA	Suspended	Approved
Gadoversetamide	Optimark®	Mallinckrodt Deutschland GmbH, Hennef, Germany	Linear	Non-Ionic	ECSA	Suspended	Approved
Gadoteridol	ProHance®	Bracco, Hennef, Germany	Cyclic	Non-Ionic	ECSA	Approved	Approved
Gadopiclenol	Vueway® Elucirem®	Bracco, Raleigh, NC, USA	Cyclic	Non-Ionic	ECSA	Approved	Approved
Gadoxetate disodium	Eovist® Primovist®	Bayer, Milano, Italy	Linear	Ionic	HSCA	Restricted	Approved
Gadobenate diemglumine	MultiHance®	Bracco, Colleretto, Italy	Linear	Ionic	HSCA	Restricted	Approved
Gadofosveset trisodium	Ablavar® Vasovist®	Bayer Pharma, Berlin, Germany	Linear	Ionic	BPA	Withdrawn	Withdrawn